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Abstract Objective: Laminin-5, a
cell adhesive molecule expressed
solely by epithelium, is known to
enhance epithelial cell migration and
repair of injured epithelium, after its
essential component c2-chain is pro-
cessed proteolytically. Our previous
study revealed circulating levels of
amino-terminal fragment of laminin
c2-chain (G2F) reflect epithelial
tumor invasiveness in carcinoma
patients, but its physiological role in
alveolar epithelial injury remains
unknown. Design: Sampling of
epithelial lining fluids or pulmonary
edema fluids from patients with acute
lung injury (ALI) or related diseases
was performed. Plasma samples were
obtained from them at the time of
disease onset or later. G2F concen-
trations were determined by
immunoassay constructed by
ourselves. Results: We found a sig-
nificantly higher amount of G2F in
pulmonary edema and epithelial lin-
ing fluids of patients with ALI, as
compared with those with the other
respiratory diseases. Their plasma
levels were also elevated significantly
early at the onset of ALI
(mean ± SD; 147 ± 82 ng/ml in
non-surviving and 90 ± 56 in sur-
viving patients) as compared with
those in the patients with cardiogenic
pulmonary edema (59 ± 36) or idio-
pathic pulmonary fibrosis (37 ± 17),
indicating alveolar epithelium rapidly
secrete laminin-5 in ALI. At 5 days
after onset, non-surviving patients
maintained higher plasma concentra-
tions (152 ± 84), but in contrast, the
levels in surviving patients declined
(71 ± 35), suggesting secretion of
laminin-5 was suppressed, associated
with recovery from ALI.
Conclusion: Circulating G2F may
be a biomarker for alveolar laminin-5
secreted early at disease onset in ALI,
potentially regulating alveolar
re-epithelialization.
Keywords Laminin  Circulation 
Acute lung injury  Alveolar
epithelial repair
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Introduction
The alveolar epithelium provides a primary defensive
barrier to the external environment, and thus is frequently
injured by inflammatory or physical stimuli in acute
respiratory distress syndrome (ARDS) or acute lung
injury (ALI) [1]. Repair of damaged alveolar epithelia is
an indispensable step in restoring the lung to its normal
architecture [2, 3]. The repair process is initiated by the
proliferation, migration and spreading of alveolar epi-
thelial cells from the intact margins into the damaged
areas [4, 5]. Proliferation and differentiation of alveolar
type-II cells are also important mechanisms in the
reconstitution of extracellular matrix (ECM) that can
promote alveolar epithelial repair [6, 7].
Laminins (LMs) are a family of high molecular
weight ECM proteins, deposited in the basement mem-
branes, also involved in cellular adhesion, growth and
differentiation [8, 9]. There are at least 15 types of LM
isoforms, resulting from a variety of combinations of a,
b and c chains [9, 10]. Laminin-5 (LM5), also recently
designated as laminin-332 [10], is a heterotrimer com-
posed of a3, b3 and c2 chains. LM5 is secreted solely by
epithelial cells and plays an important role in epithelial
cell migration especially during tumor invasion, metas-
tasis or remodeling of epithelial tissue [11–14]. LM5
enhances cellular migration when it is simultaneously
secreted into the ECM and activated via cleavage of its
essential constituent c2-chain by matrix metalloprotein-
ases (MMPs) [15, 16]. This proteolysis can release the
amino-terminal fragment of c2-chain (G2F), which is not
deposited in the ECM, and can be subsequently detected
in the peripheral blood [17]. We have developed an
immunoassay for quantification of G2F in biological
fluids and demonstrated that G2F is present in normal
circulation. G2F concentrations in circulation correlated
with the degree of carcinoma invasion in vivo, sug-
gesting the potential clinical value of this circulating
fragment as a biomarker for epithelial invasion induced
by LM5 [17].
LM5 is potentially involved in normal epithelial repair
[9, 18], and also expressed during epidermal wound
healing at the leading edge of the dermal–epidermal
junction by keratinocytes within several hours after
mechanical injury [19]. Previous studies have shown that
migration of alveolar epithelial cells is necessary during
the repair process of ALI, which requires several hours
for initiation and several days to be completed [3, 20].
However, little is known about the cell migration factors
produced or activated during injury, proliferation and
differentiation of alveolar epithelium [21]. Therefore, we
examined the relationship between disease status and
alveolar LM5 accumulation during the exudative phase in
patients with ALI, as reflected by circulating G2F levels
in several biological fluids.
Materials and methods
Collection of epithelial lining fluid (ELF)
and pulmonary edema fluid (PEF) specimens
ELF specimens were prepared according to the published
procedure [22], as shown schematically in Fig. 1. The
protocol was briefly described. Following routine pre-
medication, a flexible fiberoptic bronchoscope (Olympus
Co., Japan) was inserted into the lungs. The fiberscope
was wedged in a segmental bronchus of the right middle
lobe. The micro-sampling probe, with the cotton probe as
absorptive material, was inserted into the lungs through
the bronchoscope, and the inner probe was slowly
advanced into the distal airway for absorbing the ELFs.
The inner probe was removed, and the tip was placed in a
pre-weighed tube, weighed and stored at -80C. The
diluted solution for G2F measurements was prepared by
adding 3 ml of saline to the tube containing the triplicate
probes. The probe was then dried and weighed again to
measure the ELF volume recovered, and the dilution
factor was calculated.
Undiluted PEF samples were collected as previously
described [1, 23]. Briefly, the PEF sample was obtained
within 15 min of intubation and mechanical ventilation. A
14-French suction catheter (Becton–Dickinson, NJ) was
passed through the endotracheal tube and wedged into the
distal airways; then, gentle suction was applied to obtain
Weighed Dried & Weighed 
Saline solution
(1 ml per probe)
Suspended   Diluted ELFs
ELF
AlveoliSegmented
bronchus
Main
bronchus
Fig. 1 Schematic representation of ELF collection procedure.
Detailed procedure is described in ‘‘Materials and methods.’’
Briefly, a flexible fiberoptic bronchoscope was inserted into the
lungs. The bronchial micro-sampling probe, with the cotton probe
as absorptive materials, was inserted into the lungs through the
bronchoscope for absorbing the ELFs. The wet inner probe was
sectioned, introduced in a pre-weighed tube and weighed. The
diluted solution for measurements of biochemical constituents was
prepared by adding 3 ml of saline to the tube containing the
triplicate probes. The probe was then dried and weighed again to
measure the ELF volume recovered, and the dilution factor was
calculated
480
PEF (at least 1–2 ml), which was collected into a speci-
men trap, and 10–100 U of heparin was added to each
sample. Then, the heparinized samples were centrifuged,
and supernatants were stored at -80C.
Subjects for analysis of G2F levels
in ELFs and plasma specimens
Twenty-seven patients with ALI who were admitted
between 1999 and 2001 to the Intensive Care Unit of
Kyoto Prefectural University of Medicine Hospital or
Keio University Hospital were enrolled into the first part
of the study. ALI and ARDS were diagnosed using the
American European Consensus Conference definitions
[24]. Eligible patients met consensus conference oxy-
genation and radiographic criteria for either ALI or
ARDS, and were followed until death or hospital dis-
charge (survival). The lung injury score was calculated
according to the published algorithms [25].
Plasma anticoagulated with EDTA was collected at
onset (day 0) and at fixed intervals afterwards (days 1, 3,
5 and 7). ELF specimens were obtained only at day 0 as
described above. Control plasma samples were collected
from 15 healthy volunteers (11 males, 4 females), while
control ELF samples were obtained from 13 males and 2
females who underwent bronchoscopy to identify causes
of hemoptysis, or to examine small, solitary, peripheral
pulmonary nodules. Normal and control samples were
also obtained between 1999 and 2001 at the above
hospitals.
Plasma and ELF specimens were also collected from 5
patients with cardiogenic pulmonary edema (CPE) and 11
patients with idiopathic pulmonary fibrosis (IPF) who
were recruited from the Tokyo Women’s Medical Uni-
versity Hospital or the Keio University Hospital,
respectively. Plasma specimens were separately obtained
from 20 sepsis patients without ALI, recruited from Iwate
Medical University Hospital, diagnosed according to
published guidelines [26]. Additionally, ELF specimens
were also obtained from 12 patients with chronic
obstructive pulmonary disease (COPD), recruited from
the Hokkaido University of Medicine Hospital. All of
these samples were collected between 1999 and 2006.
The institutional review board of each center in Japan
approved the study protocol, and written informed con-
sent was obtained from either the patient or each patient’s
next of kin or legal representative before enrollment.
Subjects for analysis of G2F levels in PEF specimens
In the second part of the study, 21 patients with ALI/
ARDS as defined above and 11 control patients with CPE
were included in this study [24, 27]. In order to allow
comparison of mean concentrations of G2F in ELFs and
PEFs, samples of undiluted PEF were obtained only at the
onset of respiratory failure. These patients were enrolled
at the Moffitt Long University and San Francisco General
Hospitals in San Francisco between 1990 and 2005. The
institutional review board at University of California at
San Francisco approved the study protocol, and written
informed consent was obtained from either the patient or
each patient’s next of kin or legal representative before
enrollment. The lung injury score was also calculated
[25].
Immunoassay
The obtained specimens were stored at -80C until
usage. The concentration of soluble G2Fs was determined
as described previously [17].
Statistical analysis
Between-group statistical comparisons were performed
on mean G2F concentration data using one-way analysis
of variance (ANOVA), followed by a Bonferroni/Dunn
post-hoc test. Time course data of plasma G2F levels
were also analyzed using repeated measures ANOVA.
Statistical differences for mean PEF concentrations of
G2F between CPE and ALI patient groups were analyzed
using non-parametric statistics (Mann–Whitney U test).
Differences were regarded as statistically significant when
P \ 0.05. All calculations were performed using Stat-
View 5.0 software (SAS Institute Inc., Cary, NC).
Results
G2F levels in ELF samples of the ALI patients
In the first part of the study, we enrolled 27 patients with
ALI. Nineteen patients survived to yield a hospital mor-
tality rate of 30%. Baseline clinical features of the
surviving or non-surviving patients are shown in Table 1.
ELF samples were collected from the 25 ALI patients
(including 19 survivors and 6 non-survivors) at onset (day
0). One-way ANOVA revealed a significant difference
in the ELF levels of G2Fs among patient and control
groups (F = 6.3, P \ 0.0004). G2F levels in ELF from
these patients were ten-fold higher (mean ± SD;
6,034 ± 6,245 ng/ml) than those from 15 control subjects
(813 ± 807 ng/ml, P \ 0.0003) or compared to 12
COPD patients (350 ± 442 ng/ml, P \ 0.0003), indicat-
ing a high degree of secretion of G2F into the air spaces in
the early phase of ALI (Fig. 2). The ELF levels in these
25 ALI patients were also significantly elevated compared
to 5 control patients with CPE (1,237 ± 807 ng/ml,
481
P \ 0.02) or 11 IPF patients (2,166 ± 2,806 ng/ml,
P \ 0.02). No significant elevation of ELF levels was
observed in the patients with COPD, CPE or IPF, as
compared with those of the controls (Fig. 2). Addition-
ally, mean levels of ELF in ALI non-survivors was
increased (8,610 ± 7,556 ng/ml) compared to survivors
(5,221 ± 5,765 ng/ml), although the difference was not
statistically significant (P = 0.309, by Mann–Whitney U
test).
G2Fs levels in PEF samples of the ALI patients
In order to compare PEF levels of G2F to ELF levels, we
examined G2F concentrations in PEFs of 11 CPE patients
and 21 ALI patients. These patient characteristics were
shown in Table 2. PEF levels in the ALI subjects were
significantly higher (mean ± SD; 3,242 ± 6,813 ng/ml)
than those in the CPE patients (897 ± 798 ng/ml,
P \ 0.05), as shown in Fig. 3.
Time course of G2F levels in circulation of the ALI
patients
We quantified G2F in plasma obtained from 27 patients
with ALI (Table 1). One-way ANOVA demonstrated a
significant difference in plasma levels of G2Fs among
patients and control groups (F = 5.6, P \ 0.0001). At day
0, plasma levels of G2F in 8 non-surviving ALI patients
were significantly elevated (mean ± SD; 147 ± 82 ng/ml,
P \ 0.0001) compared with 15 control subjects (35 ±Ta
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Fig. 2 Levels of G2Fs in ELF of subjects in the early phase of ALI.
The box–whisker plots show the 25th and 75th percentiles, the
median (horizontal line within the box), and the 10th and 90th
percentiles (whiskers). Individual values below the 10th percentile
and above the 90th percentile are shown as open circles. The mean
G2F levels in the ELF samples collected from 25 patients with ALI,
at the onset time of the disease (day 0), were significantly higher
(*P \ 0.0003) than those from 15 control subjects or those from 12
COPD patients. They were also significantly elevated (**P \ 0.02)
rather than those from 5 patients with CPE or those from 11
patients with IPF
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14 ng/ml), as shown in Fig. 4. The plasma level of G2F in
17 surviving ALI patients at day 0 was moderately elevated
(90 ± 56 ng/ml) and was also significantly higher
(P \ 0.006) than control values. G2F levels were higher in
plasma from ALI non-survivors than survivors at day 0
(P \ 0.02), a difference that persisted on day 5 (71 ±
35 ng/ml for survivors vs. 152 ± 84 ng/ml in non-survi-
vors, P \ 0.003) and day 7 (57 ± 26 ng/ml for survivors
vs. 174 ± 107 ng/ml for non-survivors, P \ 0.0002)
(Fig. 4). Plasma G2F concentrations for each of the non-
surviving ALI patient groups at day 0, 1, 3, 5 or 7 were
significantly higher than those for the control group
(P \ 0.0001 on day 0, 5 or 7; P \ 0.0004 for day 1;
P \ 0.002 for day 3). In contrast, plasma G2F concentra-
tions in the surviving patient groups at day 0, 1 or 3 were
moderately elevated (P \ 0.006 for day 0; P \ 0.002 for
day 1; P \ 0.007 for day 3 vs. control group), but no dif-
ference could be detected at day 5 or 7 (P = 0.08 or 0.33 vs.
control group, respectively). Plasma levels of G2Fs were
not significantly elevated in the patients with CPE
(59 ± 36 ng/ml) or IPF (37 ± 17 ng/ml), as compared
with those in control subjects (Fig. 4).
By using repeated measures ANOVA, we also found that
time course data of plasma G2F levels in non-survivors were
statistically different from those in survivors (P \ 0.02).
Plasma G2F concentrations of the 20 patients with non-ALI
sepsis were not high (32 ± 18 ng/ml, not shown in Fig. 4),
similar to levels in the controls (35 ± 14 ng/ml).
Discussion
It is well understood that the degree of alveolar epithelial
injury is an important predictor of the outcome in ARDS/
ALI [20, 28]. However, there are currently no reliable
clinical or biological markers of the extent of alveolar
epithelial injury. Therefore, we tested the pathogenetic
significance of a novel biological molecule expressed in
specific response to the early onset of ALI.
Table 2 Comparison of physiological characteristics of the patient
groups entered in the PEF study
Disease (no. of patients) CPE (n = 11) ALI (n = 21)
Age (years) 45 ± 20 42 ± 14
Sex, no. (%)
Male 6 (54) 12 (59)
Female 5 (46) 9 (41)
Caucasian, no. (%) 6 (55) 11 (50)
Current smoker, no. (%) 1 (9) 7 (32)
Sepsis, no. (%) 0 (0) 11 (50)
Days of unassisted ventilation 19 ± 9 7 ± 10
Tidal volume (ml) 677 ± 166 620 ± 220
PaO2/FiO2 143 ± 90 74 ± 27
Lung injury scorea 2.50 ± 0.70 3.10 ± 0.50
Hospital mortality, no. (%) 2 (18) 15 (68)
Plus–minus values are mean ± SD
Tidal volumes, PaO2/FiO2 and lung injury scores were observed the
onset of the diseases
a Calculated according to the published methods [25]. Higher
scores indicate more severe illness
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and ALI. The box–whisker plots show the 25th and 75th
percentiles, the median (horizontal line within the box), and the
10th and 90th percentiles (whiskers). Individual values below the
10th percentile and above the 90th percentile are shown as open
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The levels in the patients with CPE or IPF were not significantly
higher than those in the control subjects
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Recent experimental data suggest that accelerating re-
epithelialization of the alveolar barrier leads to the reso-
lution of ALI [3, 21, 28]. Re-epithelialization can occur
even in the absence of the proliferation of epithelial cells
or the recruitment of stem cells immediately after the
injury [3, 4]. Previous studies hypothesized that most of
alveolar repair is mediated by type-II pneumocytes that
migrate and differentiate into type-I cells under stimula-
tion of some component of ECM proteins in newly
deposited basement membranes [29]. We prospectively
expected LM5 may be expressed simultaneously with
type-II pneumocyte migration during the early phase
alveolar epithelial repair after the onset of ALI.
The alveolar basement membrane contains several
isoforms of LMs, and several functions for these adhesion
molecules have been elucidated [6, 30]. LM5 attracted our
interest because it is specifically expressed in epithelium
and stimulates cell migration, especially keratinocyte
remodeling or carcinoma cell invasion [11–14]. Our prior
experimental studies suggest that physiological epithelial
cell migration can be estimated by the circulating levels of
G2F, derived from the essential component c2-chains of
LM5 [17]. Thus, we hypothesized circulating G2F levels
are associated with alveolar epithelial migration to repair
the injured lung.
Expression of LM5 in type-II pneumocytes was reported
previously, but its function is unknown [30]. In this study,
for the first time, we report that significant increases of G2F
are found in the circulation of ALI patients at the onset of
acute respiratory failure (Figs. 2, 3, 4). Therefore, we
speculate that the alveolar epithelial cells acting to repair the
injured sites should prominently express migration-active
LM5, generated by proteolytic shedding of the G2F domain,
and that soluble G2F is consequently released from the
alveolar surface into the ELF and diffuses from the ECM
into the circulation of ALI patients. The degree of G2F
secretion at the onset of ALI may be independent of disease
severity, as migration of alveolar epithelial cells may reflect
the drive to repair damage per se, rather than the actual
extent of injury. As satisfactory repair of the injured epi-
thelium is achieved, recovery of function in patients
responding to therapy is associated with a decrease of cir-
culating G2Fs at day 5 and 7 (Fig. 4). In contrast, the plasma
G2F levels in ALI patients unresponsive to therapy
remained significantly elevated at days 5 or 7, suggesting
that some physiological signaling might operate to promote
continued LM5 synthesis and proteolytic cleavage of its c2-
chain by type-II pneumocytes in the absence of adequate
tissue repair, since alveolar epithelial function was not
sufficiently normalized in these cases (Fig. 4). We also
found that mean G2F concentrations in ELF samples from
the ALI patients are comparable with those in PEF speci-
mens from another group of the ALI patients, supporting the
conclusion that G2F levels in ELFs obtained during routine
bronchoscopic monitoring can accurately reflect the quan-
tity of them released into alveolar epithelial surfaces.
Approximately half of the ALI patients usually
received pulse therapy of steroids, which may not affect
their G2F levels (data not shown), because none of
increased G2F was found in the patients with COPD or
IPF probably treated with any steroids.
We should not be regardless of potential bias in our
analysis using multiple specimens from six different
medical centers, because their diagnosis cannot be always
standardized. Our study is the initial step to estimate
significance of circulating G2F in respiratory disorders,
using rarely obtainable specimens such as ELF or PEF.
Increase of G2Fs in the ELF demonstrated they are
mainly derived from injured alveolar tissues, as well as
their increase in the PEF. Some further trials without
potential institutional bias will be recommended, proba-
bly assisted by our present study.
Immunohistochemical observation of LM5 c2 chains in
IPF lung tissues has been already reported, demonstrating
that regenerating epithelial cells in IPF can actually syn-
thesize c2 chains, but their expression levels in IPF are
significantly reduced than those in cryptogenic organizing
pneumonia [31]. This evidence suggested that alveolar
LM5 accumulation can be induced preferably at the early
phase of pulmonary injury rather than during the chronic
phase of IPF, corresponding with our present results that
G2F levels in ALI patients at the disease onset were sig-
nificantly higher than those in IPF patients (Figs. 2, 4). We
have also preliminarily detected LM5 expression in small
population of pneumocytes in ALI by immunohistochem-
ical technique (unpublished observation), predicting G2Fs
are endogenously secreted from injured alveolar epithe-
lium. Some further studies are needed to investigate tissue
expression of LM5 in the patients with ALI, whose circu-
lating G2F increased significantly.
Several proteases may be secreted from inflammatory
leukocytes as they transmigrate into injured lung tissue. If
LM5 is deposited in alveolar ECM, it may be degraded
into small fragments in ALI. However, circulating G2F
levels appear to be independent of such random proteol-
ysis, since G2F is unlikely to be deposited in epithelial
ECM [32]. Shedding of G2F from LM5 heterotrimers in
vivo is critically mediated by membrane-type 1 MMP,
and LM5 processed by the other MMPs cannot promote
epithelial cell migration [16, 33]. We infer that the
physiological action of LM5 to initiate epithelial repair
may be imparted specifically by membrane-type 1 MMP
cleavage and not random proteolysis.
In conclusion, we report that circulating G2F increases
substantially at disease onset in ALI patients. In the
patients recovering from ALI, G2F concentrations
declined in parallel with their clinical improvement; in
contrast, prolonged elevation of G2F was associated with
poorer prognosis, potentially suggesting that circulating
G2F may be a useful biomarker to monitor the pneumo-
cyte re-epithelialization process during alveolar epithelial
repair in ALI/ARDS patients.
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